The Budget Blindside: Did Pharma Fight The Wrong Battle?
Executive Summary
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
You may also be interested in...
Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.
Medicare Aduhelm Coverage Policy Overrules FDA: Can Two Wrongs Make A Right?
Plenty of people believe the US FDA should never have approved Biogen/Eisai’s Alzheimer’s therapy. But does that really mean it is okay for the Medicare agency to decide as a matter of policy that the drug has not been proven safe and effective?